Undisclosed MYC c-mod
/ Dewpoint Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 11, 2026
Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate
(GlobeNewswire)
- "The MYC DC is a first-in-class small molecule designed to disrupt MYC-driven oncogenic transcription by modulating the aberrant biomolecular condensates that organize transcriptional control in cancer cells....The MYC DC was selected based on a comprehensive preclinical data package demonstrating potency and specificity in MYC-dependent cellular systems, favorable in vivo pharmacology, including tumor regressions in MYC-dependent models....Dewpoint is prepared to advance the MYC DC through IND-enabling studies while continuing to deepen its understanding of MYC condensate biology across cancer models."
Pipeline update • Preclinical • Oncology
October 14, 2025
Dewpoint Therapeutics Announces Presentation at AACR-NCI-EORTC 2025
(GlobeNewswire)
- "Oral condensate modulators (c-mods) demonstrate efficient and selective killing of cancer cells in multiple pre-clinical models of MYC-driven cancers."
Preclinical • Solid Tumor
September 10, 2025
Dewpoint Therapeutics…announced the closing of its Series D financing to advance DPTX3186, a first-in-class condensate modulator (c-mod), into clinical trials by year-end 2025 and deliver early clinical proof-of-concept by the end of 2026
(GlobeNewswire)
- "It will also accelerate development of Dewpoint’s first-in-class c-mod targeting MYC...while strengthening ongoing collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma. The financing provides operational runway into early 2027."
Financing • New trial • Gastric Cancer • Ovarian Cancer
March 26, 2025
Dewpoint Therapeutics announces upcoming presentations at AACR 2025
(GlobeNewswire)
- "Dewpoint will present two posters at AACR; Condensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of cancer; C-mods modulate the oncogenic function of historically undruggable targets MYC and beta catenin."
Preclinical • Oncology • Ovarian Cancer
1 to 4
Of
4
Go to page
1